Congress continues to invest $1.5 billion in SAMHSA's state opioid response grants.
Looking forward, the Committee is focused on identifying ways to stem this crisis and bring relief to the millions of Am...
The country is in the midst of an epidemic unlike any in recent history.
The crisis has continued to evolve, and the challenges that we face have continued to evolve along with it.
Today, the subcommittee on Oversight and Investigations is holding a hearing entitled 'A Public Health Emergency: State ...
Today, the Committee continues its bipartisan efforts to combat the opioid crisis.
data challenges we identified in our 2008 report continue to make it difficult for FDA to accurately identify establishm...
I look forward to working with my colleagues to advance bipartisan reform that will actually lower drug prices.
Because the FDA can't possibly test every new drug that comes into the U.S., inspections of drug manufacturers abroad ar...
This hearing should not be interpreted as an indictment of foreign drug manufacturing generally.
Today's hearing focuses on an area of longstanding concern to this committee that has taken on increased importance: The...